Recruiting
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States - CA180-653
Updated: 28 April, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
Inclusion Criteria: 1. ≥ 18 years at the time of Ph+ CP-CML diagnosis 2. Newly diagnosed chronic phase of Ph+ CP-CML, confirmed with cytogenetic and/or molecular testing at baseline 3. Treatment-naïve and initiating treatment with dasatinib, imatinib, nilotinib or bosutinib 4. Willingness and ability to comply with routine office visits Exclusion Criteria: 1. Any other prior or active non-CML active malignancy for which the patient is receiving treatment 2. Participation in a therapeutic clinical trial for CML disease
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
